Clinical Trial Update: Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing homoharringtonine with hydroxyurea for chronic myeloid leukemia that has not responded to interferon alfa has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Homoharringtonine (homoharringtonine)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Leukemia | Phase 3 | Status: TERMINATED